TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06689085: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Sponsor: Halozyme Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$3,347,224

Rescue Site Savings

+$2,215,768

Unlock Full NCT06689085 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06689085 Rescue Dossier →